Specific nucleic acid amplification with compounded selectivity
US-2016153036-A1 · Jun 2, 2016 · US
US9796748B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9796748-B2 |
| Application number | US-201214114961-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 2, 2012 |
| Priority date | May 2, 2011 |
| Publication date | Oct 24, 2017 |
| Grant date | Oct 24, 2017 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The invention provides systems and methods for spatial sequestration of elements in nucleic acid circuits.
Opening claim text (preview).
What is claimed is: 1. A synthetic system comprising (a) a first three-dimensional nucleic acid nanostructure shaped in the form of a container comprising walls, an interior surface and an exterior surface, (b) a first tethered nucleic acid attached to the interior surface of the first three-dimensional nucleic acid nanostructure and partially hybridized to a first output signal nucleic acid, wherein the first tethered nucleic acid contains a toehold domain that is not complementary to the first output signal nucleic acid, (c) a second three-dimensional nucleic acid nanostructure shaped in the form of a container comprising walls, an interior surface and an exterior surface, and (d) a second tethered nucleic acid attached to the interior surface of the second three-dimensional nucleic acid nanostructure and partially hybridized to a second output signal nucleic acid, wherein the second tethered nucleic acid contains a toehold domain that is not complementary to the second output signal nucleic acid, and wherein the toehold domain of the second tethered nucleic acid is complementary to a domain of the first output signal nucleic acid. 2. The system of claim 1 , wherein the first and second tethered nucleic acids are not integral to the first and second nucleic acid nanostructures. 3. The system of claim 1 , wherein the first and second nucleic acid nanostructures are independently selected from the group consisting of closed nucleic acid nanostructures and open nucleic acid nanostructures. 4. The system of claim 3 , wherein the open nucleic acid nanostructures comprise two open ends. 5. The system of claim 3 , wherein the closed nucleic acid nanostructures comprise a nucleic acid lock. 6. The system of claim 1 , further comprising one or more upstream and/or downstream nucleic acid nanostructures. 7. The system of claim 6 , wherein the one or more of the upstream and/or downstream nucleic acid nanostructures comprise tethered nucleic acid. 8. A method comprising contacting a first input signal nucleic acid with the system of claim 1 in an amount effective to release the second output signal nucleic acid from the second nucleic acid nanostructure. 9. The system of claim 6 , wherein the one or more of the upstream and/or downstream nucleic acid nanostructures comprise free flowing nucleic acids. 10. The system of claim 9 , wherein the free flowing nucleic acids are output signal nucleic acids. 11. The system of claim 1 , wherein the first nucleic acid nanostructures and/or the second nucleic acid nanostructure comprises an agent. 12. The system of claim 11 , wherein the agent is or comprises a therapeutic agent. 13. The system of claim 11 , wherein the agent is or comprises a detectable marker. 14. The system of claim 1 , wherein the first nucleic acid nanostructures and/or the second nucleic acid nanostructure comprises a plurality of tethered nucleic acids. 15. The system of claim 1 , wherein the first nucleic acid nanostructures and/or the second nucleic acid nanostructure comprises a plurality of free flowing nucleic acids. 16. The system of claim 1 , wherein the length of the toehold domain of the first tethered nucleic acid is 4-12 nucleotides. 17. The system of claim 1 , wherein the length of the toehold domain of the second tethered nucleic acid is 4-12 nucleotides. 18. The system of claim 1 , wherein the first nucleic acid nanostructure is a deoxyribonucleic acid (DNA) nanostructure. 19. The system of claim 1 , wherein the second nucleic acid nanostructure is a DNA nanostructure.
Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors · CPC title
Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery · CPC title
with deoxyribosyl as saccharide radical · CPC title
Composed of biological material · CPC title
using radioactive material · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.